Literature DB >> 31392165

An immediate, single instillation of mitomycin C in non-muscle invasive bladder cancer: can we define which patients do and do not benefit?

Judith Bosschieter1, R Jeroen A van Moorselaar1, Jakko A Nieuwenhuijzen1.   

Abstract

Entities:  

Year:  2019        PMID: 31392165      PMCID: PMC6642968          DOI: 10.21037/tau.2019.03.08

Source DB:  PubMed          Journal:  Transl Androl Urol        ISSN: 2223-4683


× No keyword cloud information.
  8 in total

1.  Re: Maurizio A. Brausi. Challenging the EAU guidelines regarding early repeat transurethral resection. Eur Urol Suppl 2011;10:e5-7.

Authors:  Rauf Taner Divrik; Ali F Sahin
Journal:  Eur Urol       Date:  2012-03-21       Impact factor: 20.096

2.  The effect of timing of an immediate instillation of mitomycin C after transurethral resection in 941 patients with non-muscle-invasive bladder cancer.

Authors:  Judith Bosschieter; R Jeroen A van Moorselaar; André N Vis; Tessa van Ginkel; Birgit I Lissenberg-Witte; Goedele M A Beckers; Jakko A Nieuwenhuijzen
Journal:  BJU Int       Date:  2018-01-31       Impact factor: 5.588

3.  Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.

Authors:  Judith Bosschieter; Jakko A Nieuwenhuijzen; Tessa van Ginkel; André N Vis; Birgit Witte; Don Newling; Goedele M A Beckers; R Jeroen A van Moorselaar
Journal:  Eur Urol       Date:  2017-07-10       Impact factor: 20.096

4.  An immediate, single intravesical instillation of mitomycin C is of benefit in patients with non-muscle-invasive bladder cancer irrespective of prognostic risk groups.

Authors:  Judith Bosschieter; Jakko A Nieuwenhuijzen; André N Vis; Tessa van Ginkel; Birgit I Lissenberg-Witte; Goedele M A Beckers; R Jeroen A van Moorselaar
Journal:  Urol Oncol       Date:  2018-07-29       Impact factor: 3.498

5.  EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.

Authors:  Marko Babjuk; Andreas Böhle; Maximilian Burger; Otakar Capoun; Daniel Cohen; Eva M Compérat; Virginia Hernández; Eero Kaasinen; Joan Palou; Morgan Rouprêt; Bas W G van Rhijn; Shahrokh F Shariat; Viktor Soukup; Richard J Sylvester; Richard Zigeuner
Journal:  Eur Urol       Date:  2016-06-17       Impact factor: 20.096

Review 6.  Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?

Authors:  Richard J Sylvester; Willem Oosterlinck; Sten Holmang; Matthew R Sydes; Alison Birtle; Sigurdur Gudjonsson; Cosimo De Nunzio; Kikuo Okamura; Eero Kaasinen; Eduardo Solsona; Bedeir Ali-El-Dein; Can Ali Tatar; Brant A Inman; James N'Dow; Jorg R Oddens; Marek Babjuk
Journal:  Eur Urol       Date:  2015-06-16       Impact factor: 20.096

7.  A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences.

Authors:  Ingela Berrum-Svennung; Torvald Granfors; Staffan Jahnson; Hans Boman; Sten Holmäng
Journal:  J Urol       Date:  2007-11-12       Impact factor: 7.450

8.  Redefining the role of immediate intravesical instillation of mitomycin C in non-muscle invasive bladder cancer.

Authors:  Deepak Batura
Journal:  Transl Androl Urol       Date:  2018-12
  8 in total
  1 in total

1.  Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Abridged version.

Authors:  Bimal Bhindi; Ronald Kool; Girish S Kulkarni; D Robert Siemens; Armen G Aprikian; Rodney H Breau; Fadi Brimo; Adrian Fairey; Christopher French; Nawar Hanna; Jonathan I Izawa; Louis Lacombe; Victor McPherson; Ricardo A Rendon; Bobby Shayegan; Alan I So; Alexandre R Zlotta; Peter C Black; Wassim Kassouf
Journal:  Can Urol Assoc J       Date:  2021-08       Impact factor: 1.862

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.